CannAmide (palmitoylethanolamide) / SciSparc - LARVOL DELTA

Adjunctive therapea - a promising method in the treatment of periodontal disease. (PubMed, Clin Oral Investig) - "The results of the current study showed that the adjunctive use of "Armenicum" reduced signs of inflammation compared to standard SRP treatment alone. Periodontal therapy using Armenicum paste application can be considered as a promising method in the treatment of periodontitis."

Clinical • Journal • Dental Disorders • Inflammation • Periodontitis

Clearmind Medicine Announces International Patent Application for Preventing and Treating Depression (GlobeNewswire) - "Clearmind Medicine Inc...announced that it has submitted its tenth patent application under the international Patent Cooperation Treaty ('PCT'), as part of its ongoing collaboration with SciSparc Ltd...a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system. The patent applications refer to the novel proprietary composition of Clearmind’s MEAI compound (5-methoxy-2-aminoindane) with Palmitoylethanolamide ('PEA'), the active ingredient of SciSparc’s proprietary CannAmide, for preventing and/or treating depression."

Patent • CNS Disorders • Depression

Clearmind Medicine Expanding IP Portfolio with New US Patent Application for Treatment of Depression (GlobeNewswire) - "Clearmind Medicine Inc...announces the filing of a patent application seeking to protect its unique combination of MEAI and SciSparc's Palmitoylethanolamide (PEA) for the treatment of depression....This patent is an addition to Clearmind's robust intellectual property portfolio that includes patents for MEAI as a binge behavior regulator, as an alcoholic beverage substitute and others."

Patent • CNS Disorders • Depression

Israel-Based Clearmind Medicine Files Patent Applications for Three Unique Combinations of Future Psychedelic-Based Compounds (GlobeNewswire) - “Clearmind Medicine Inc…announced that it has filed three provisional patent applications with the United States Patent and Trademark Office (USPTO), for unique combinations of future psychedelic-based compounds, as part of its ongoing collaboration with pharmaceutical company SciSparc Ltd….The patent applications refer to novel proprietary combinations of 3,4-Methyl​enedioxy​methamphetamine (MDMA), Ibogaine, and Ketamine, each with Palmitoylethanolamide (PEA), the active ingredient of SciSparc's proprietary CannAmide™.”

Patent • Borderline Personality Disorder • CNS Disorders • Depression • Inflammation • Major Depressive Disorder • Pain

SciSparc Initiates Commercial Production of its CannAmide Pills (PRNewswire) - "SciSparc Ltd.(formerly known as Therapix Biosciences Ltd.)...announced it has begun commercial production of its proprietary Palmitoylethanolamide (PEA) oral tablet formulation, CannAmide™. Recommended for use as an anti-inflammatory to help relieve chronic pain, the tablets will be marketed to pharmacies and other retail outlets across Canada following our entering into a distribution agreement."

Commercial • Pain